Risk factors for silent cerebral infarction in immune‐mediated thrombotic thrombocytopenic survivors

Documenti analoghi

• Immune‐mediated thrombotic thrombocytopenic purpura with ischaemic cerebral infarction preceding onset of thrombocytopenia and microangiopathic haemolytic anaemia: A case report
  di: Masahito Uchihara, et al.
  Pubblicazione: (2024)
• Facing the bleeding risk of caplacizumab in postpartum immune thrombotic thrombocytopenic purpura in constrained resource settings
  di: José Rojas‐Suarez, et al.
  Pubblicazione: (2025)
• Assessment of neurocognitive functioning in sickle cell disease and thalassaemia and the association with silent cerebral infarcts, cerebral haemodynamics and oxygen metabolism
  di: Liza Afzali‐Hashemi, et al.
  Pubblicazione: (2025)
• Successful management of refractory immune‐mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti‐VWF nanobody caplacizumab
  di: Roman R. Schimmer, et al.
  Pubblicazione: (2024)
• Monoclonal gammopathy of thrombotic significance in a nutshell
  di: Adam J. Kanack, et al.
  Pubblicazione: (2026)